Wassil Jim 4

Accession 0001649094-25-000039

CIK 0001649094other

View on SEC.gov Company Profile

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 9:14 PM ET

Size

25.0 KB

Accession

0001649094-25-000039

Insider Transaction Report

Form 4

Period: 2025-02-27

Vaxcyte, Inc.PCVX

Wassil Jim

CHIEF OPERATING OFFICER

Transactions

Sale
Common Stock
2025-03-03$73.07/sh−5,915$432,215→ 157,016 total
Award
Common Stock
2025-02-28$73.02/sh+5,649$412,490→ 159,070 total
Tax Payment
Common Stock
2025-02-28$73.02/sh−2,869$209,494→ 156,201 total
Exercise/Conversion
Common Stock
2025-03-03$2.42/sh+2,638$6,384→ 157,569 total
Exercise/Conversion
Common Stock
2025-03-03$5.35/sh+5,362$28,687→ 162,931 total
Tax Payment
Common Stock
2025-02-28$73.02/sh−1,270$92,735→ 154,931 total
Tax Payment
Common Stock
2025-03-03$72.10/sh−3,015$217,381→ 151,916 total
Award
Common Stock
2025-02-27+21,726→ 153,421 total
Sale
Common Stock
2025-03-03$73.84/sh−2,085$153,950→ 154,931 total
Award
Stock Option (right to buy)
2025-02-27+72,536→ 72,536 total
Exercise: $74.22Exp: 2035-02-26→ Common Stock (72,536 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-03-03−2,638→ 0 total
Exercise: $2.42Exp: 2029-12-16→ Common Stock (2,638 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-03-03−5,362→ 71,664 total
Exercise: $5.35Exp: 2030-04-17→ Common Stock (5,362 underlying)

Footnotes (8)

[F1]Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
[F2]Represents RSUs issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. The RSUs are fully vested upon the date of grant.
[F3]Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
[F4]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
[F5]The price reported is a weighted-average price. The shares were sold at prices ranging from $72.50 to $73.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F6]The price reported is a weighted-average price. The shares were sold at prices ranging from $73.51 to $74.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F7]1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
[F8]Option is fully vested and exercisable.

Documents

1 file

4
wk-form4_1741054462.xmlPrimary
FORM 4

Issuer

Vaxcyte, Inc.

CIK 0001649094

→

Entity typeother

Related Parties

filerCIK 0001813798

Filing Metadata

Form type: 4
Filed: Mar 2, 7:00 PM ET
Accepted: Mar 3, 9:14 PM ET
Size: 25.0 KB

View on SEC.gov